Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

This study is testing an advanced cell therapy called CAR-T cell therapy using donor cells to treat B-cell acute lymphoblastic leukemia (B-ALL, a type of blood cancer) that has come back or stopped responding to standard treatments. **You may be eligible if...** - You are 14 years old or older - You have been diagnosed with B-cell ALL - Your leukemia has relapsed (come back) or has not responded to prior treatment - You have bone marrow or blood involvement from the cancer **You may NOT be eligible if...** - Your relapse is entirely outside the bone marrow (isolated extramedullary relapse only) - You have severe organ dysfunction - You have active uncontrolled infections - You do not meet organ function requirements for this therapy Talk to your doctor to see if this trial is right for you.